Modeling the cost-effectiveness of adjuvant osimertinib in resected EGFR-mutant non-small cell lung cancer patients.

被引：3
|
作者：
Lemmon, Christopher
Zabor, Emily Craig
Pennell, Nathan A.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.8527
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8527
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Specific TCR profiles predict clinical outcome of adjuvant EGFR-TKIs for resected EGFR-mutant non-small cell lung cancer
    Si-Yang Maggie Liu
    Cunte Chen
    Yi-Kai Zhang
    Wen-Zhao Zhong
    Yi-Long Wu
    Si-Yang Liu
    Yangqiu Li
    [J]. Biomarker Research, 11
  • [32] Specific TCR profiles predict clinical outcome of adjuvant EGFR-TKIs for resected EGFR-mutant non-small cell lung cancer
    Liu, Si-Yang Maggie
    Chen, Cunte
    Zhang, Yi-Kai
    Zhong, Wen-Zhao
    Wu, Yi-Long
    Liu, Si-Yang
    Li, Yangqiu
    [J]. BIOMARKER RESEARCH, 2023, 11 (01)
  • [33] Optimization of Dosing for EGFR-Mutant Non-Small Cell Lung Cancer with Evolutionary Cancer Modeling
    Chmielecki, Juliann
    Foo, Jasmine
    Oxnard, Geoffrey R.
    Hutchinson, Katherine
    Ohashi, Kadoaki
    Somwar, Romel
    Wang, Lu
    Amato, Katherine R.
    Arcila, Maria
    Sos, Martin L.
    Socci, Nicholas D.
    Viale, Agnes
    de Stanchina, Elisa
    Ginsberg, Michelle S.
    Thomas, Roman K.
    Kris, Mark G.
    Inoue, Akira
    Ladanyi, Marc
    Miller, Vincent A.
    Michor, Franziska
    Pao, William
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2011, 3 (90)
  • [34] Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer?
    Patel, Shruti R.
    Neal, Joel W.
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (07) : 1631 - 1635
  • [35] Diffuse Lung Metastases in EGFR-Mutant Non-Small Cell Lung Cancer
    Digumarthy, Subba R.
    Mendoza, Dexter P.
    Padole, Atul
    Chen, Tianqi
    Peterson, P. Gabriel
    Piotrowska, Zofia
    Sequist, Lecia, V
    [J]. CANCERS, 2019, 11 (09)
  • [36] Economic analysis of osimertinib in previously untreated EGFR-mutant advanced non-small cell lung cancer in Canada
    Ezeife, Doreen A.
    Kirk, Veronica
    Chew, Derek S.
    Nixon, Nancy A.
    Lee, Roy
    Le, Lisa W.
    Chan, Kelvin K. -W.
    Leighl, Natasha B.
    [J]. LUNG CANCER, 2018, 125 : 1 - 7
  • [37] An exploration of the clinical progression models of osimertinib in the treatment of advanced EGFR-mutant non-small cell lung cancer
    Shi, Yue
    Jiang, Yingying
    Pan, Banzhou
    Wang, Zihan
    Li, Hang
    Ma, Yuxin
    Liu, Yilin
    He, Kang
    Wang, Zhitong
    Lu, Jianwei
    Shi, Meiqi
    Shen, Bo
    Zhou, Guoren
    Yin, Rong
    Rossi, Antonio
    Ito, Kentaro
    Santarpia, Mariacarmela
    Um, Sang-Won
    Wang, Xiaohua
    Chen, Cheng
    Feng, Jifeng
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2022, : 817 - 831
  • [38] Neurological death in patients with EGFR-mutant non-small cell lung cancer.
    Ramotar, Matthew
    Barnes, Sierra
    Doherty, Mark
    Shultz, David Benjamin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [39] Cost-effectiveness of osimertinib in the treatment of advanced EGFR-mutated non-small cell lung cancer: a systematic review
    Nargesi, Shahin
    Dolatshahi, Zeinab
    Rezapour, Aziz
    Alipour, Vahid
    Souresrafil, Aghdas
    Farabi, Hiro
    Javadmoosavi, Seyed Arash
    Safakhah, Mandana
    Moradi, Najmeh
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (04) : 543 - 554
  • [40] Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer
    Bertranou, Evelina
    Bodnar, Carolyn
    Dansk, Viktor
    Greystoke, Alastair
    Large, Samuel
    Dyer, Matthew
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (02) : 113 - 121
12345